股本结构
单位：万股
| 公告日期 | 2025-11-14 | 2025-11-14 | 2025-08-14 | 2025-07-22 | 2025-05-15 | 2025-05-15 |
|---|---|---|---|---|---|---|
| 证券总股本 | 62.03 | 57.46 | 57.46 | 52.98 | 546.20 | 294.44 |
| 普通股本 | 62.03 | 57.46 | 57.46 | 52.98 | 546.20 | 294.44 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2025-11-14 | 2025-09-30 | 2025-08-14 | 2025-07-22 | 2025-05-15 | 2025-03-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2025-11-14 | 62.03 | 未披露 | 定期报告 | 2025-11-14 |
| 2025-11-14 | 57.46 | 未披露 |
更多>>
From June 30, 2025 to September 30, 2025
Stock cancelled during stock split rounding
Stock issued for warrants exercised
|
2025-09-30 |
| 2025-08-14 | 57.46 | 未披露 | 定期报告 | 2025-08-14 |
| 2025-07-22 | 52.98 | 未披露 |
更多>>
a 1-for-12 reverse split of the Company’s common stock
|
2025-07-22 |
| 2025-05-15 | 546.20 | 未披露 | 定期报告 | 2025-05-15 |
| 2025-05-14 | 326.94 | 未披露 |
更多>>
Common stock offered 325,000 shares by the company
|
2025-05-14 |
| 2025-05-15 | 294.44 | 未披露 |
更多>>
From December 31, 2024 to March 31, 2025
Common stock issued for cash, net
Stock cancelled during stock split rounding
|
2025-03-31 |
| 2025-03-20 | 294.44 | 未披露 | 定期报告 | 2025-03-20 |
| 2025-02-19 | 149.93 | 未披露 |
更多>>
A 1-for-50 reverse split of its common stock
|
2025-02-21 |
| 2025-01-03 | 7496.25 | 未披露 | 定期报告 | 2025-01-03 |
| 2024-11-14 | 5748.67 | 未披露 | 定期报告 | 2024-11-14 |
| 2024-10-24 | 4957.49 | 未披露 |
更多>>
Common Stock Offered 3,700,000 shares by the company
|
2024-10-24 |
| 2024-11-14 | 3344.64 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Common stock issued for cash and warrants, net
Common stock issued for license agreement
|
2024-09-30 |
| 2024-08-14 | 3214.64 | 未披露 | 定期报告 | 2024-08-14 |
| 2024-08-07 | 2595.96 | 未披露 | 定期报告 | 2024-08-05 |
| 2024-07-30 | 1007.50 | 未披露 | 定期报告 | 2024-07-30 |
| 2024-07-05 | 286.83 | 未披露 |
更多>>
Common stock offered 1,425,000 shares by the company
|
2024-07-05 |
| 2024-08-14 | 144.33 | 未披露 |
更多>>
From March 31, 2024 to June 30, 2024
Exercise of warrants, net
Common stock issued for cash and warrants, net
Adjustment related to reverse stock split
|
2024-06-30 |
| 2024-06-27 | 144.33 | 未披露 |
更多>>
Common stock offered 568,000 shares by the company
|
2024-06-27 |
| 2024-06-27 | 87.53 | 未披露 | 定期报告 | 2024-06-25 |
| 2024-06-17 | 84.53 | 未披露 |
更多>>
Common stock offered 336,000 shares by the company
|
2024-06-17 |
| 2024-06-17 | 50.93 | 未披露 | 定期报告 | 2024-06-14 |
| 2024-06-10 | 39.16 | 未披露 | 定期报告 | 2024-06-06 |
| 2024-06-05 | 32.50 | 未披露 |
更多>>
1-for-50 reverse split of its common stock
|
2024-06-05 |
| 2024-06-05 | 1625.00 | 未披露 | 定期报告 | 2024-06-04 |
| 2024-05-15 | 1185.19 | 未披露 | 定期报告 | 2024-05-15 |
| 2024-05-15 | 1066.89 | 未披露 |
更多>>
From December 31, 2023 to March 31, 2024
Common stock issued for cash, net
Exercise of warrants, net
|
2024-03-31 |
| 2024-04-10 | 1063.49 | 未披露 | 定期报告 | 2024-03-21 |
| 2024-01-31 | 843.03 | 未披露 |
更多>>
Common stock offered 2,215,667 shares by the company
|
2024-02-01 |
| 2024-04-01 | 621.46 | 未披露 |
更多>>
From December 31, 2022 to December 31, 2023
Common stock issued for cash, net
Stock-based compensation
Exercise of warrants, net
|
2023-12-31 |
| 2023-12-08 | 621.46 | 未披露 | 定期报告 | 2023-12-08 |
| 2023-11-14 | 524.86 | 未披露 | 定期报告 | 2023-11-14 |
| 2023-11-14 | 420.71 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Common stock issued for cash, net
Stock-based compensation
|
2023-09-30 |
| 2023-08-14 | 420.19 | 未披露 | 定期报告 | 2023-08-11 |
| 2023-08-14 | 414.10 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Common stock issued for cash, net
Exercise of warrants
|
2023-06-30 |
| 2023-05-01 | 414.33 | 未披露 | 定期报告 | 2023-04-29 |
| 2023-05-15 | 222.63 | 未披露 |
更多>>
From December 31, 2022 to March 31, 2023
Exercise of warrants
|
2023-03-31 |
| 2023-03-31 | 222.63 | 未披露 | 定期报告 | 2023-03-29 |
| 2023-03-31 | 161.73 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Common stock issued for cash, net
Exercise of warrants
|
2022-12-31 |
| 2022-12-05 | 148.16 | 未披露 |
更多>>
Common stock offered 147,000 shares by the company
|
2022-12-16 |
| 2022-11-28 | 133.00 | 未披露 |
更多>>
CNS Pharmaceuticals, Inc. announced a 1-for-30 reverse split of its common stock, effective at 4:01 PM ET November 28, 2022. As a result of the Reverse Stock Split, the number of shares of common stock outstanding will be reduced from approximately 40.03 million shares as of September 30, 2022 to approximately 1.33 million shares.
|
2022-11-29 |
| 2022-08-12 | 4003.25 | 未披露 | 定期报告 | 2022-06-30 |
| 2022-03-03 | 4003.25 | 未披露 | 定期报告 | 2022-03-03 |
| 2022-03-03 | 2792.72 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Common stock and warrants issued for cash, net
Exercise of warrants
Stock-based compensation
|
2021-12-31 |
| 2021-11-12 | 2792.10 | 未披露 | 定期报告 | 2021-11-12 |
| 2021-11-12 | 2746.07 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Stock-based compensation
|
2021-09-30 |
| 2021-08-13 | 2746.07 | 未披露 | 定期报告 | 2021-08-12 |
| 2021-08-13 | 2737.95 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021.
Common stock issued for cash and subscription receivable, net
Stock-based compensation
|
2021-06-30 |
| 2021-04-30 | 2535.91 | 未披露 | 定期报告 | 2021-04-28 |
| 2021-05-13 | 2535.28 | 未披露 |
更多>>
From December 31, 2020 To March 31, 2021
Common stock issued for cash, net
Exercise of warrants
Stock-based compensation
|
2021-03-31 |
| 2021-02-12 | 2530.09 | 未披露 | 定期报告 | 2021-02-12 |
| 2021-02-12 | 2385.62 | 未披露 |
更多>>
From December 31, 2019 to December 31, 2020
Common stock and warrants issued for cash, net
Common stock issued for deferred offering costs
|
2020-12-31 |
| 2020-12-28 | 2310.62 | 未披露 |
更多>>
1.Common stock the company is offering 5,000,000 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 18,106,151 shares outstanding as of December 21, 2020.
|
2020-12-28 |
| 2020-12-21 | 1810.62 | 未披露 | 定期报告 | 2020-12-21 |
| 2020-11-12 | 1665.22 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Common stock issued for deferred offering costs
|
2020-09-30 |
| 2020-09-25 | 1665.22 | 未披露 | 定期报告 | 2020-09-15 |
| 2020-03-12 | 1645.02 | 未披露 |
更多>>
from December 31, 2018 to December 31, 2019
Common stock issued for cash
Common stock issued for services
Common stock issued for extinguishment of convertible notes payable and accrued interest
Conversion of SAFE agreements
|
2019-12-31 |
| 2019-12-20 | 1645.02 | 未披露 | 定期报告 | 2019-12-20 |
| 2019-11-08 | 1571.20 | 未披露 |
更多>>
1.Common stock we are offering 2,125,000 shares
2.The number of shares of common stock to be outstanding after this offering is based on 13,587,004 shares outstanding as of November 7, 2019
|
2019-11-08 |
| 2019-12-20 | 1353.70 | 未披露 |
更多>>
from June 30, 2019 to September 30, 2019
Common stock issued for cash
|
2019-09-30 |
| 2019-08-22 | 1358.70 | 未披露 | 定期报告 | 2019-08-20 |
| 2019-08-22 | 1353.70 | 未披露 | 定期报告 | 2019-06-30 |
| 2019-06-28 | 1269.45 | 未披露 |
更多>>
from December 31, 2017 to December 31, 2018
Common stock issued for cash
Common stock issued for services
Common stock and warrants issued for extinguishment of convertible notes payable and accrued interest
|
2018-12-31 |
| 2018-06-15 | 1053.60 | 未披露 | 定期报告 | 2018-06-01 |
From June 30, 2025 to September 30, 2025
Stock cancelled during stock split rounding
Stock issued for warrants exercised
a 1-for-12 reverse split of the Company’s common stock
Common stock offered 325,000 shares by the company
From December 31, 2024 to March 31, 2025
Common stock issued for cash, net
Stock cancelled during stock split rounding
A 1-for-50 reverse split of its common stock
Common Stock Offered 3,700,000 shares by the company
From June 30, 2024 to September 30, 2024
Common stock issued for cash and warrants, net
Common stock issued for license agreement
Common stock offered 1,425,000 shares by the company
From March 31, 2024 to June 30, 2024
Exercise of warrants, net
Common stock issued for cash and warrants, net
Adjustment related to reverse stock split
Common stock offered 568,000 shares by the company
Common stock offered 336,000 shares by the company
1-for-50 reverse split of its common stock
From December 31, 2023 to March 31, 2024
Common stock issued for cash, net
Exercise of warrants, net
Common stock offered 2,215,667 shares by the company
From December 31, 2022 to December 31, 2023
Common stock issued for cash, net
Stock-based compensation
Exercise of warrants, net
From June 30, 2023 to September 30, 2023
Common stock issued for cash, net
Stock-based compensation
From March 31, 2023 to June 30, 2023
Common stock issued for cash, net
Exercise of warrants
From December 31, 2022 to March 31, 2023
Exercise of warrants
From December 31, 2021 to December 31, 2022
Common stock issued for cash, net
Exercise of warrants
Common stock offered 147,000 shares by the company
CNS Pharmaceuticals, Inc. announced a 1-for-30 reverse split of its common stock, effective at 4:01 PM ET November 28, 2022. As a result of the Reverse Stock Split, the number of shares of common stock outstanding will be reduced from approximately 40.03 million shares as of September 30, 2022 to approximately 1.33 million shares.
From December 31, 2020 to December 31, 2021
Common stock and warrants issued for cash, net
Exercise of warrants
Stock-based compensation
From June 30, 2021 to September 30, 2021
Stock-based compensation
From March 31, 2021 to June 30, 2021.
Common stock issued for cash and subscription receivable, net
Stock-based compensation
From December 31, 2020 To March 31, 2021
Common stock issued for cash, net
Exercise of warrants
Stock-based compensation
From December 31, 2019 to December 31, 2020
Common stock and warrants issued for cash, net
Common stock issued for deferred offering costs
1.Common stock the company is offering 5,000,000 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 18,106,151 shares outstanding as of December 21, 2020.
From June 30, 2020 to September 30, 2020
Common stock issued for deferred offering costs
from December 31, 2018 to December 31, 2019
Common stock issued for cash
Common stock issued for services
Common stock issued for extinguishment of convertible notes payable and accrued interest
Conversion of SAFE agreements
1.Common stock we are offering 2,125,000 shares
2.The number of shares of common stock to be outstanding after this offering is based on 13,587,004 shares outstanding as of November 7, 2019
from June 30, 2019 to September 30, 2019
Common stock issued for cash
from December 31, 2017 to December 31, 2018
Common stock issued for cash
Common stock issued for services
Common stock and warrants issued for extinguishment of convertible notes payable and accrued interest